GlassScriptPhysician profile
Ora Esfahani
NPI 1508319542
$6,938.81
in general payments reported to CMS, 2019-2025
21 companies · $1,811 in 2025
The $1,811 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,644 · 2020: $562 · 2021: $490 · 2022: $676 · 2023: $936 · 2024: $820 · 2025: $1,811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,386 · Entertainment: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,385.89 |
| Entertainment | $180.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,100.05 | 2019-2025 | |
| Alcon Vision LLC | $1,029.18 | 2019-2025 | Dailies Total1, Tryptyr, Clareon |
| Glaukos Corporation | $727.67 | 2020-2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $655.91 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $598.32 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $531.74 | 2019-2021 | |
| Abbvie INC. | $381.78 | 2022-2025 | |
| Optos, INC. | $309.44 | 2019-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $269.40 | 2024-2025 | Miebo, Xiidra |
| Coopervision INC. | $259.31 | 2020-2024 | Onefit Contact Lens, Paragon Hds100 Contact Lens |
| Biotissue Holdings INC. | $207.09 | 2023 | |
| Allergan, INC. | $199.40 | 2020-2022 | |
| Shire North American Group INC | $147.17 | 2019 | |
| Kala Pharmaceuticals, INC. | $119.32 | 2020 | |
| Eyevance Pharmaceuticals LLC | $98.08 | 2019-2023 | Flarex |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optovue, INC. | $95.84 | 2019 | |
| Sun Pharmaceutical Industries INC. | $91.58 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $55.73 | 2019 | |
| Amgen INC. | $23.30 | 2025 | Tepezza |
| Abb Con-Cise Optical Group LLC | $21.13 | 2020 | |
| Oyster Point Pharma, INC. | $17.37 | 2025 | Ryzumvi, Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ora Esfahani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.